SUNNYVALE, Calif., Aug. 22, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017.
Q4 Fiscal 2017 and Recent Highlights
• Gross orders of $85.7 million driven by strong demand from both the new Radixact™ System and the CyberKnife® System with the InCise™ Multileaf Collimator (“MLC”)
• Revenue increased 18 percent compared to prior fiscal year to $112.1 million driven by strong year over year growth from the Americas and APAC regions
• Generated operating income of $2.8 million compared to an operating loss of $3.0 million in the prior fiscal year; generated a net loss of $5.3 million compared to a prior fiscal year net loss of $7.2 million
• Adjusted EBITDA of $10.3 million as compared to $5.0 million in prior fiscal year
• Cash, cash equivalents, investments and short-term restricted cash increased sequentially by $23.6 million to $108.8 million at June 30, 2017
• New study data in a peer-reviewed journal published online shows TomoTherapy® System IMRT as superior to RapidArc in achieving local control of head and neck cancer
